Previous Close | 906.18 |
1-Year Change | 58.62% |
6-Months Change | 17.26% |
3-Months Change | 2.28% |
Moving Avg (50d) | 896.11 |
Moving Avg (200d) | 776.94 |
ESG Rating | - |
Exchange | NYSE |
Market Cap. | 0.815T |
Beta (3-Years) | 0.57 |
Revenue Growth (ttm) | 9.69% |
Net Profit Margin (ttm) | 15.55% |
Return On Assets (ttm) | 8.61% |
EPS (ttm) | 5.52 |
PE Ratio (ttm) | 164.16 |
Dividend Yield | 0.48% |
Asset Description: | Eli Lilly and Company |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
888.056 | 860.871 | 842.747 | 815.562 | 770.253 | 724.944 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.